Robert Yates to be Named Chief Operating Officer of Ortho-Clinical Diagnostics, Inc. (OCD)
June 16 2014 - 7:00AM
Newly Created Role to Begin
Pending Close of Acquisition of OCD by The Carlyle Group
Experienced Executive Has Proven Record of Delivering
Significant Business Success in Diagnostics and Life Science
Markets
Global alternative asset manager The Carlyle Group (Nasdaq:CG)
today announced that Robert Yates will become Chief Operating
Officer of Ortho-Clinical Diagnostics, Inc. ("OCD"), subject to the
close of Carlyle's acquisition of OCD from Johnson & Johnson,
which is expected in mid-2014. In this newly-created role, Mr.
Yates will report directly to incoming OCD Chairman and CEO Dr.
Martin Madaus. Mr. Yates will also be appointed to OCD's board of
directors.
"We are excited at the prospect of having Robert's diagnostics
and executive leadership experience on board at OCD," said Stephen
H. Wise, Carlyle Managing Director. "In partnership with Martin,
Robert will contribute significantly to OCD's transformation into a
global standalone diagnostics leader." Dr. Martin Madaus added,
"Robert's strategic perspective and proven leadership abilities
align well with OCD's new priorities of profitable growth and
differentiated innovation for our customers and for patients around
the world."
Mr. Yates will join OCD from Merck KGaA where he was President
and CEO of EMD/Merck Millipore, its global life sciences
division. At EMD Millipore, Robert finalized the complex
transition of Millipore from a standalone company into one
integrated, global Life Science division. He increased the
discipline and execution on market-led innovation, redefined the
go-to-market approach, and implemented a suite of unified global
processes, systems and business tools while optimizing the
organizational structure. Under Robert´s leadership, EMD Millipore
consistently delivered above market quality growth and eliminated
systemic product quality and supply related disruptions.
Robert joined Millipore from the diagnostics division of Roche,
where he led Roche Applied Science, the life sciences business
located in Penzberg, Germany. In that role, he also served as a
member of the Diagnostics Executive Committee. Robert joined Roche
in Indianapolis, Indiana in 1988 and held various roles in R&D,
Engineering and Operations before being appointed Global Head of
Business Development and Licensing in Basel, Switzerland in 2003.
He possesses a wealth of experience in the Diagnostics and Life
Science industries and a strong background in integrating global
businesses, building performance cultures and delivering strategic
business value. He holds a Bachelor of Science degree in Electrical
Engineering from Purdue University in Indiana.
About Ortho-Clinical Diagnostics, Inc.
Ortho-Clinical Diagnostics, Inc. delivers the high-quality in
vitro diagnostic products that give healthcare professionals around
the world the knowledge they need to make better treatment
decisions sooner. The company serves the global transfusion
medicine community with donor screening and blood typing products
to help ensure every patient receives blood that is safe, the right
type and the right unit. Ortho-Clinical Diagnostics, Inc. also
brings sophisticated information management, testing technologies
and automation and interpretation tools to clinical laboratories
worldwide to help them run more efficiently and improve patient
care. For more information, visit www.orthoclinical.com
About The Carlyle Group
The Carlyle Group (Nasdaq:CG) is a global alternative asset
manager with approximately $199 billion of assets under management
across 120 funds and 133 fund of funds vehicles as of March 31,
2014. Carlyle's purpose is to invest wisely and create value on
behalf of its investors, many of whom are public pensions. Carlyle
invests across four segments – Corporate Private Equity, Real
Assets, Global Market Strategies and Solutions – in Africa, Asia,
Australia, Europe, the Middle East, North America and South
America. Carlyle has expertise in various industries, including:
aerospace, defense & government services, consumer &
retail, energy, financial services, healthcare, industrial, real
estate, technology & business services, telecommunications
& media and transportation. The Carlyle Group employs more than
1,600 people in 38 offices across six continents.
Web: www.carlyle.com Videos: www.youtube.com/onecarlyle Tweets:
www.twitter.com/onecarlyle Podcasts:
www.carlyle.com/about-carlyle/market-commentary
CONTACT: The Carlyle Group
Liz Gill: +1 (202) 729-5385
Elizabeth.gill@carlyle.com
Carlyle (NASDAQ:CG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Carlyle (NASDAQ:CG)
Historical Stock Chart
From Jul 2023 to Jul 2024